Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy comprising sglt inhibitors and dpp4 inhibitors

A technology for DPP4 and inhibitors, applied in the field of compositions that increase the concentration of active GLP-1 in mammalian plasma, can solve problems such as reducing glucose concentration

Active Publication Date: 2010-12-29
MITSUBISHI TANABE PHARMA CORP
View PDF77 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, inhibition of SGLT causes excretion of blood glucose into the urine, resulting in lower plasma glucose concentration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy comprising sglt inhibitors and dpp4 inhibitors
  • Combination therapy comprising sglt inhibitors and dpp4 inhibitors
  • Combination therapy comprising sglt inhibitors and dpp4 inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0479] Effect of SGLT inhibitors on plasma active GLP-1 concentrations in glucose-treated DPP4-deficient rats

[0480] (a) Animals:

[0481] DPP4-deficient male Fisher rats (purchased from Charles River Japan, Inc.)

[0482] (b) method:

[0483] (b-1) Preparation and administration of test compound

[0484] The test compound was suspended in a 0.5% carboxymethylcellulose solution containing 0.2% Tween 80 (Tween 80) at the dose shown in Table 1, and was orally administered to the test group at a volume of 5 mL / kg. The vehicle control group received oral administration of 0.5% carboxymethylcellulose solution containing 0.2% Tween 80 (Tween 80) at a volume of 5 mL / kg. Glucose solution (2 g / kg / 5 ml) was orally administered immediately after compound or vehicle administration. (b-2) Blood collection process and determination of active GLP-1 concentration in plasma

[0485] Blood was collected from the tail vein of unanesthetized rats immediately before glucose administration a...

Embodiment 2

[0498] Synergistic Effect of SGLT Inhibitor and DPP4 Inhibitor on Concentration of Active GLP-1 in Plasma of Glucose-Treated Normal Rats

[0499] (a) Animals:

[0500] DPP4-positive male Fisher rats (purchased from Japan SLC, Inc.)

[0501] (b) method:

[0502] (b-1) Preparation and administration of test compound

[0503] Each test compound was suspended in a 0.5% carboxymethylcellulose solution containing 0.2% Tween 80 at the dose shown in Table 2, and was orally administered to the test group at a volume of 5 mL / kg. The vehicle control group received oral administration of 0.5% carboxymethylcellulose solution containing 0.2% Tween 80 (Tween 80) at a volume of 5 mL / kg. Glucose solution (2 g / kg / 5 ml) was orally administered immediately after compound or vehicle administration.

[0504] (b-2) Blood collection process and determination of active GLP-1 concentration in plasma

[0505] Blood was collected from the tail vein of unanesthetized rats immediately before glucose a...

Embodiment 3

[0520] Effects of SGLT inhibitors and DPP4 inhibitors on plasma active GLP-1 concentrations in glucose-treated diabetic mice

[0521] (a) Animals:

[0522] Male BKS.Cg - +Lepr db / +Lepr db / Jc1 mouse; animal model of type 2 diabetes (purchased from CLEA Japan, Inc.)

[0523] (b) method:

[0524] (b-1) Preparation and administration of test compound

[0525] Each test compound was suspended in a 0.5% carboxymethylcellulose solution containing 0.2% Tween 80 at the dose shown in Table 3, and was orally administered to the test group at a volume of 5 mL / kg. The vehicle control group received oral administration of 0.5% carboxymethylcellulose solution containing 0.2% Tween 80 (Tween 80) at a volume of 5 mL / kg. Glucose solution (2 g / kg / 5 ml) was orally administered immediately after compound or vehicle administration.

[0526] (b-2) Blood collection process and determination of active GLP-1 concentration in plasma

[0527] Blood was collected from the tail vein of unanesthet...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the combination is useful for prevention or treatment of conditions such as diabetes and diseases related to diabetes.

Description

technical field [0001] The present invention relates to a composition and method for increasing the concentration of active GLP-1 in mammalian plasma. The present invention also relates to a composition and method for alleviating a condition by increasing the concentration of active GLP-1 in plasma. Background technique [0002] Glucagon-like peptide-1 (GLP-1) is an incretin hormone released by L-cells in the lower small intestine following food ingestion. GLP-1 has been shown to stimulate insulin secretion from pancreatic β-cells in response to glucose and to increase pancreatic β-cell mass. GLP-1 has also been shown to reduce the rate of gastric emptying and promote feelings of fullness. However, GLP-1 is rapidly cleaved by dipeptidyl peptidase 4 (DPP4), rendering it biologically inactive. Therefore, DPP4 inhibitors are considered useful as antidiabetic or antiobesity agents. [0003] Sodium-glucose co-transporters (SGLTs), mainly found in the intestine and kidney, are...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/401A61K31/7004A61K31/7008A61K45/06A61P3/10
CPCA61K31/7008A61K31/401A61K31/7004A61K45/06C07H7/04A61P13/12A61P25/00A61P25/02A61P25/08A61P25/14A61P25/16A61P25/28A61P27/02A61P27/12A61P3/00A61P3/04A61P3/06A61P43/00A61P5/50A61P9/00A61P9/10A61P9/12A61P3/10A61K2300/00A61K31/40A61K31/496A61K31/4985A61K31/5377A61K31/7034A61K31/7056A61K31/706
Inventor 植田喜一郎荒川健司松下泰明
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com